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Obtaining diagnostic specimens, notably to monitor disease course in cancer patients 
undergoing therapy, is an emerging area of research, however, with few clinical 
implications so far in the field of Neuro-oncology. Specifically for patients with primary 
brain tumors where repeat biosampling from the tumor and clinical decision making 
based on neuroimaging alone remain challenging, this area may assume a central 
role. In principle, sampling could focus on blood, cerebrospinal fluid or urine with 
differential sensitivities and specificities of findings that differ between specific 
parameters and target molecules. These include protein, mRNA, miRNA, cell-free 
DNA, either freely circulating or as cargo of extracellular vesicles, as well circulating 
tumor cells. The most solid biomarkers are those directly reflecting neoplastic 
disease, e.g., in the case of primary brain tumors isocitrate dehydrogenase mutation 
or epidermal growth factor receptor variant III. Importantly, the main goals of liquid 
biopsy marker development are to better understand response to therapy, natural 
evolution and emergence of resistant clones, rather than obviating the need for 
surgical interventions which remain to be a mainstay of therapy for the vast majority 
of primary brain tumors. 
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Liquid biopsies refer to the analysis of body fluids to inform on the presence or on the 
molecular evolution of neoplastic disease. The body fluids studied include blood, 
cerebrospinal fluid (CSF), and urine, but also any other conceivable 
compartmentalized fluid collection like cysts or reservoirs. While the use of liquid 
biopsies in systemic cancer has long been considered an interesting tool, much less 
is known about the potential clinical value of liquid biopsies in locally circumscribed 
diseases like primary brain tumors, notably given the common absence of extra-
central nervous system spread in these instances. Yet, specifically with primary brain 
tumors where repeat tissue sampling may be challenging, easily accessible sources 
of molecular data to monitor the disease course such as urine or plasma and even 
CSF are highly attractive. 
How and why the liquid biomarkers reach these compartments and determinants of 
their half-life therein remains incompletely understood, but these topics are areas of 
ongoing research efforts. The blood brain barrier serves the purpose of excluding 
molecules and particles from the brain parenchyma, but whether it plays any role in 
keeping these within the brain and restricting their exiting from the tumor tissue into 
blood, lymphatic system or CSF remains largely unclear. 
Soluble biologically active molecules may not only be freely circulating, but may also 
constitute part of cargo circulating within subcellular structures referred to as 
extracellular (micro)vesicles. Since cancer cells may release more such material than 
normal cells, cancer cell-derived vesicles may contribute to overall pathogenesis of 
cancer [1]. Characterization of these structures and of their content requires specific 
techniques of centrifugation and sample processing [2] [3] [4] . These extracellular 
vesicles may shape not only the microenvironment, but also modulate systemic 
processes in cancer patients including glioblastoma [5]. Here we review recent 
developments of liquid biopsies for primary brain tumors, excluding primary central 
nervous system lymphoma. 
 
 
2. Serum  
 
Proteins 
The detection of proteins as tumor markers in serum or plasma remains challenging 
because of the high protein content of serum and because proteins only prove the 
presence of neoplastic disease if they themselves are affected by mutation in the 
disease context, e.g., the detection of epidermal growth factor receptor (EGFR) 
variant III (EGFRvIII) protein in serum would prove the existence of an EGFRvIII-
mutant tumor somewhere. Among primary brain tumors, only subgroups of germ cell 
tumors can be diagnosed based on the synthesis and release of high amounts of α1-
fetoprotein or β-human choriogonadotrophin. Other protein biomarkers play no role in 
clinical routine so far. 
 
mRNA 
Freely circulating mRNA may be rapidly degraded, but extracellular vesicles may 
contain mRNA that disclose the presence of cancer including glioblastoma, e.g., 
EGFRvIII mRNA was detected in serum-derived extracellular vesicles from 7 of 25 
glioblastoma patients, although two of these patients reportedly had EGFRvIII-non-
mutant tumors [5]. In a study of WHO grade III and IV gliomas, EGFRvIII mRNA was 
detected in 39.5% of tumor samples, but in 44.7% of paired serum exosome 
samples, resulting in a sensitivity of 81% and a specificity of 79%, setting tissue 
detection as the reference. Very surprisingly, given the need for EGFR amplification 
to acquire the EGFRvIII mutation, wild-type EGFR mRNA was exclusively found in 
tumor tissue in this study, but never in the exosomes [6]. 
 
miRNA 
In an almost historical study, it was explored whether specific miRNA fingerprints can 
be detected in the peripheral blood of glioblastoma patients. Of 1158 miRNA 
examined, 52 were significantly deregulated, and two miRNA, miR-128 which was 
increased and miR-342-3p which was decreased in tumor patients relative to healthy 
controls, remained significant after correction for multiple testing. Furthermore, a 
machine learning algorithm was able to distinguish between glioblastoma samples 
and control samples with specificity of 79% and sensitivity of 83% [7]. More recently, 
miR-100 has been proposed to be decreased in the serum of glioblastoma patients, 
and its levels normalized after treatment [8]. Like other soluble markers, miRNA 
species may also be circulating with microvesicles [9], and elevated levels of the 
glioblastoma-associated miR-21 were also detected in extracellular vesicles in serum 
from glioblastoma patients [5]. 
 
Cell-free tumor DNA 
Compared with metastatic cancers, detection of ctDNA in the serum of patients 
with primary brain tumors turned out to be more challenging and may require 
more sophisticated technology [10]. 
O6-methyl guanine DNA methyltransferase (MGMT) promoter methylation is the 
single most important predictive biomarker in glioblastoma although establishing a 
widely accepted methodology for its assessment has remained challenging. Since 
MGMT promoter methylation rarely changes in the course of disease [11], its 
monitoring in the periphery is of limited clinical relevance. Yet, the technical feasibility 
of detecting promoter-methylated MGMT gene sequences has in principle been 
demonstrated [12]. In a more extensive study, paired serum and tumor samples were 
assessed for MGMT promoter methylation status by methylation-specific PCR or by 
pyrosequencing. Methylation was detected in serum by both methods, but 
concordance of serum data with tissue results was low. Overall sensitivities were 
31% and 38% whereas specificity was good; it was higher for methylation-specific 
PCR (96%) than for pyrosequencing (76%) [13]. Thus this technology may not yet be 
used for clinical decision making. 
In general, detection of ctDNA requires the presence of typical mutations that can be 
readily detected by simple sequencing techniques and which prove the presence of 
tumor. Typical examples in gliomas include EGFRvIII or isocitrate dehydrogenase 
(IDH) 1 or 2 mutations. Furthermore, promoter-mutated telomerase reverse 
transcriptase (TERTp) is a tumor-defining molecular lesion e.g. detected in the 
peripheral blood of a patient with metastatic spinal myxopapillary ependymoma [14]. 
Various clinical trial activities, notably the development of a specific vaccine, 
rindopepimut, for patients with glioblastomas carrying the EGFRvIII mutation 
triggered efforts at determining EGFRvIII status by peripheral liquid biopsies, at least 
as a means to monitor immune-mediated elimination of the target antigen. Moreover, 
EGFRvIII has the advantage of being without exception a tumor-defining molecular 
marker. Yet, the negative outcome of the ACT IV trial decreased interest in EGFRvIII 
as a target in glioblastoma which also was observed not to be stably expressed over 
time [15], although agents targeting EGFRvIII, including bispecific antibodies, 
continue to be developed. Recent large screening efforts indicate that half of the 
patients with primary brain tumors may reveal relevant mutations when plasma cell-
free DNA is subjected to next generation panel sequencing [16]. 
 
Circulating tumor cells (CTC) 
In contrast to the detection of the biomarkers discussed above, the detection of tumor 
cells outside the central nervous system provides direct evidence of systemic spread 
of primary brain tumors and nourishes the unresolved question of why there are so 
few clinically diagnosed metastases from primary brain tumors outside the central 
nervous system. Several methods have been employed to detect CTC in the 
peripheral blood of primary brain tumor patients (Table). The detection rates varied 
from 20% to 70%. Where studied, detection of CTC has been associated with inferior 
outcome. The relevance of CTC clusters that have so far only been reported once in 






As indicated above for plasma, α1-fetoprotein or β-human choriogonadotrophin can 
also be assessed in the CSF as a means to aid in the differential diagnosis of 




Detection of mutant EGFRvIII became a prime target also in the CSF because of its 
tumor specificity and the interest in monitoring response to EGFRvIII-directed 
treatment, notably vaccination [15]. EGFRvIII mRNA was detected in CSF-derived 
extracellular vesicles of 14 of 23 patients with EGFRvIII-mutant tumors whereas only 
one of 48 patients with EGFRvIII-non-mutant tumors showed EGFRvIII mRNA in the 
CSF, for a sensitivity of 61% and a specificity of 98% for analysis of CSF extracellular 
vesicles to detect positive EGFRvIII status [18]. These authors reported similar 
sensitivity and specificity when comparing lumbar versus cisternal CSF. 
 
miRNA 
miRNA profiles in the CSF of glioblastoma patients have been reported to correlate 
with those found in the tumor tissue. A signature of nine miRNA to distinguishing 
glioblastoma patients from patients with other conditions was identified. In a 
prospective validation study, sensitivity and specificity of this signature were 67% and 
80% for cisternal CSF, and 28% and 95% for lumbar CSF. The authors furthermore 
reported no difference when analyzing extracellular vesicles from CSF versus crude 
CSF [19]. 
 
Cell-free tumor DNA 
Many academic institutions have introduced gene panel sequencing into their 
standard work-up of primary brain tumors. In principle, such gene panels can also 
easily be applied to CSF samples [20]. Such approaches may be particularly useful in 
situations where tissue availability is limited or where biopsies may be refused by 
patients and caregivers or not feasible because of lack of local surgical expertise or 
where extent of resection is no prognostic factor, e.g., in patients with brain stem 
gliomas [21] [22] [23]. Using mutations detected in the tumor as a reference, the rate 
of positive CSF findings has been estimated at 74%, and lack of lesion proximity to 
the CSF space correlated with negative findings [24]. Assessing the mutational status 
of IDH2, TP53, TERT, ATRX (α-thalassemia/mental retardation syndrome, 
nondeletion type, X-linked), histone H3F3A, and HIST1H3B, which allows to classify 
the majority of diffuse gliomas of adulthood, in the CSF resulted in the correct 
diagnosis in 17 of 20 cases [25]. CSF ctDNA profiling can also be used to detect 
newly acquired mutations in the course of disease or in response to treatment [26] 
[27]. However, sensitivity overall remains to vary by tumor burden, proximity to CSF 
space, and grade of malignancy, and, e.g., no ctDNA was detected in three patients 
with intramedullary spinal ependymoma [28]. 
 
Metabolomics 
Metabolomic studies to characterize the CSF of primary brain tumor patients are 
limited, but have potential for specific treatment monitoring situations. Pathway 
analyses revealed different alterations in various metabolic pathways when 
comparing CSF from patients with IDH-mutant and IDH-wildtype gliomas, and CSF 
from patients with IDH-mutant gliomas showed increased levels of D-2-
hydroxyglutarate in the CSF [29]. 
 
4. Urine 
Urine has been less well studied as a source of biochemical information in brain 
tumor patients. Elevated levels of tissue inhibitor of metalloproteinases 3 and basic 
fibroblast growth factor have been advanced as specific for juvenile pilocytic 
astrocytoma [30].  
Urine may be more suitable for metabolic studies than for the assessment of other 
biomarkers covered herein. While two studies failed to demonstrate altered levels of 
the putative oncometabolite, 2-hydroxyglutarate, in the urine of patients with IDH-
mutant gliomas  [31], the latter study somewhat surprisingly reported that its urine 
levels are decreased in these patients, accordingly, the ratio of plasma/urine is 
increased [32] . Neither the biological basis nor clinical implications are clear at this 
point. Furthermore, a subsequent study indeed, while confirming no change in serum 
levels, reported rather increased levels of 2-hydroxyglutarate in patients with IDH-
mutant gliomas [33]. 
 
5. Outlook 
Potential clinical applications of liquid biopsies for patients with primary brain tumors 
include the initial diagnostic work-up, potentially scenarios where knowledge of 
molecular status would impact surgical strategies, monitoring of response to therapy, 
and the differentiation of tumor progression from pseudoprogression which refers to 
scenarios where imaging suggests progression while there is none. Furthermore, 
metabolic profiling has been advanced as a potential tool to identify individuals at risk 
of developing a glioma [34]. 
Liquid biopsies from various body fluids hold a lot of promise to complement the 
current diagnostic repertoire for patients with primary brain tumors. Furthermore, the 
power of genome wide characterization of tumor-educated platelets remains to 
be applied to patients with primary brain tumors [35]. To implement results 
from liquid biopsies into clinical practice will require standardization of 
sampling, storage and analysis in prospective studies on defined tumor 
entities and disease stages to identify the clinical scenarios in which liquid 
biopsies may be of most value.  
Moreover, liquid biopsies are a valuable research tool that should be incorporated 
increasingly into prospective clinical trials in Neuro-Oncology. In particular, liquid 
biopsies may turn out to be useful as a complementary diagnostic approach to 
clinical assessment and neuroimaging in clinical situations which have 
remained challenging to date, e.g., differentiation of progression from 
pseudoprogression, assessment of tumor evolution associated with emerging 
druggable mutations, or assessment of disease extension in brain tumors 
associated with leptomeningeal spread. In contrast, liquid biopsies should not be 
primarily conceptualized as an opportunity to obviate the need for surgical 
interventions or disease monitoring. This is because surgery has commonly a 
therapeutic, not only a diagnostic intent, and neuroimaging provides essentially 
different information than liquid biopsies. 
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Reference Tumors Parameter Technology Findings 
     
Serum     
Skog et al. 2008 Glioblastoma mRNA in 
extracellular vesicles 
RT-PCR EGFRvIII mRNA can be detected 
Manda et al. 2018 « high-grade » 
gliomas 
mRNA in exosomes RT-PCR EGFRvIII mRNA more often detected 
in exosomes than in tumors 
Roth et al. 2011 Glioblastoma miRNA miRNA chip hybridization Specific miRNA profiles can be 
detected in glioblastoma 
Zhang et al. 2019 Glioblastoma miR-100 RT-PCR miR-100 decreased in glioblastoma, 
normalization after treatment 
Santangelo et al. 
2018 
Gliomas miR-21, miR-222, 
miR-124-3p 
RT-PCR expression of miR-21, miR-222 and 
miR-124-3p was measured in 
exosomes isolated from serum 
Estival et al. 2019 Glioblastoma ctDNA Methylation-specific PCR or 
pyrosequencing 
MGMT promoter methylation status 
can be assessed in plasma, but 
sensitivity remains low 
Piccioni et al. 2019 Primary brain 
tumors 
ctDNA sequencing 50% detection rate of relevant 
mutations 
     
Macarthur et al. 
2014 
 CTC Telomerase activity-based 
assays 
72% detection rate 
Sullivan et al. 2014 Glioblastoma CTC Antibody cocktail (SOX2, 
tubulin, EGFR, A2B5, c-MET) 
39% detection rate 
Müller et al. 2014 Glioblastoma CTC Immune staining for glial 
fibrillary acidic protein 
21% detection rate 
Gao et al. 2016 Gliomas CTC CEP8-FISH (centromeric 
probe for chromosome 8 
fluorescent in situ 
hybridization 
77% detection rate of CTC 
Krol et al. 2018 Glioblastoma CTC Antigen-independent 
enrichment using Parsortix® 
technology 
First report of CTC clusters in 
glioblastoma 
     
     
CSF     
Figueroa et al. 
2017 
Glioblastoma mRNA in 
extracellular vesicles 
RT-PCR of vesicles isolated 
by ultracentrifugation 
EGFRvIII status scan be detected with 
low sensitivity, but high specificity 
Akers et al. 2017 Glioblastoma miRNA RT-PCR Glioblastoma CSF shows a 
characteristic miRNA signature 
Wang et al. 2015 Primary brain 
tumors 
ctDNA Sequencing The majority of tumor-specific 
mutations can be detected in the CSF 
Pentsova et al. 
2016 
Primary brain 
tumors and brain 
metastases 
ctDNA Sequencing ctDNA assessment can be used for 
monitoring 





ctDNA digital droplet PCR No reliable detection of ctDNA 
Huang et al. 2017 Brain stem 
glioma 
ctDNA Sequencing or mutation-
specific PCR 
Histone H3 mutations can be detected 
in the CSF 




ctDNA targeted exome sequencing 
and droplet digital PCR 
Sequencing of IDH2, TP53, TERT, 
ATRX, H3F3A, and HIST1H3B allows 
to diagnose the majority of diffuse 
gliomas 




H3K27M digital droplet PCR ctDNA can be used to detect H3K27M 
mutations and to document response 
to radiotherapy 
Miller et al. 2019 Gliomas ctDNA Sequencing ctDNA assessment can be used to 
monitor tumor evolution 
Pan et al. 2019 Brain stem 
gliomas 
ctDNA Gene panel sequencing Very high sensitivity of ctDNA in the 
CSF 
Gershanov et al. 
2017 
Medulloblastoma CTC Fluorescence lifetime imaging 
microscopy (FLIM) 
Novel technique to assess tumor cell 
spread in the CSF 
 
 
 
